Investigative Review of The Cigna Group

The Mathematics of Impossibility

The central metric defining the PxDx scandal is not a dollar amount, a unit of time: 1. 2 seconds. This is the average duration Cigna medical directors spent reviewing a patient’s claim before rejecting it, according to an analysis of internal company records from 2022. In that fleeting moment, less time than it takes to read a single sentence, a doctor ostensibly evaluated a patient’s medical history, the specific procedure requested, and the clinical justification provided by the attending physician. The speed suggests that no such evaluation took place. Instead, the “review” functioned as a digital rubber stamp, applying a medical license to an algorithmic decision.

The of this operation defies the physical limits of human cognition. Over a two-month period in 2022, Cigna doctors denied more than 300, 000 requests for payment using the PxDx system. One specific medical director, Dr. Cheryl Dopke, signed her name to roughly 60, 000 denials in a single month. To achieve this volume through genuine medical review, a doctor would need to work 24 hours a day, every day, without breaks, processing a new complex medical file every 43 seconds. The 1. 2-second average recorded in the data reveals that the doctors were not reading files. They were batch-signing rejections prepared by a computer.

The “Click and Submit” Assembly Line

The method allowing this velocity is a feature of the PxDx dashboard that permits bulk processing. A former Cigna medical director described the workflow to investigators, stating, “We literally click and submit. It takes all of ten seconds to do 50 at a time.” This admission exposes the reality behind the company’s claim that a medical director reviews every denial. While a human technically interacts with the software, the interaction is limited to selecting a batch of pre-flagged claims and authorizing their mass rejection.

This process removes the physician from the clinical equation. The algorithm, not the doctor, identifies the gap between the procedure code and the diagnosis code. The algorithm flags the claim as “improper.” The doctor’s role is reduced to a clerical formality, required only because state laws mandate that a licensed medical professional must make the final determination on medical need denials. By batching these decisions, Cigna adhered to the letter of the law while violating its spirit. The signature on the denial letter implies a doctor applied their medical judgment to the patient’s unique case. The timestamps prove they did not.

Architect of the Auto-Denial

The intellectual father of this system is Dr. Alan Muney, Cigna’s former Chief Medical Officer. Muney, who previously implemented similar cost-containment strategies at UnitedHealthcare, designed PxDx to automate the rejection of claims that did not perfectly match a pre-approved list of diagnosis-procedure pairs. His philosophy prioritized administrative speed over granular clinical review. Muney explicitly noted that requiring company doctors to manually review each claim rejection would be an “administrative hassle.”

This “hassle” is what patients pay premiums for: the assurance that a qualified expert consider their health needs before refusing coverage. By treating medical review as an to be eliminated, Muney’s system converted the insurance claim process into a negative-option billing pattern. The system assumes the claim is invalid if it triggers a code mismatch, and the load shifts entirely to the patient or provider to appeal, a process few navigate successfully. Cigna’s internal data shows that only about 5% of policyholders appeal these denials, meaning the 1. 2-second rejection is the final word for the vast majority of patients.

Legal Mandates vs. Algorithmic Reality

State insurance regulations, such as those in California, are explicit about the requirements for denying medical care. They demand a “thorough, fair and objective” investigation. A review lasting 1. 2 seconds cannot be thorough. It cannot be fair. It is objective only in the sense that a guillotine is objective, it falls where it is set, without regard for the neck beneath it. Class action lawsuits, including Veinbergs v. Cigna and Kisting-Leung v. Cigna, have seized on this, arguing that the PxDx system constitutes a breach of contract and a violation of state consumer protection laws.

The legal argument centers on the definition of “medical need.” A determination of need requires examining the patient’s specific circumstances. A 50-year-old woman with a family history of ovarian cancer requires a different diagnostic lens than a 20-year-old with no risk factors, even if the billing codes are identical. PxDx ignores these nuances. It sees only the code. If the code for a transvaginal ultrasound does not pair with a diagnosis code Cigna accepts for that test, the claim is flagged for denial. The medical director, seeing only a list of flagged items, approves the denial without opening the patient’s file to see why the doctor ordered the test. The 1. 2-second timestamp confirms that the patient’s history remained a closed book.

The Illusion of Oversight

Cigna defends the system by arguing that PxDx is used only for “low-cost” procedures and that it accelerates payments for correct claims. They assert that the system does not deny care, only payment for care already rendered. This distinction is meaningless to a patient facing a surprise bill for hundreds or thousands of dollars. also, the “low-cost” defense obscures the aggregate financial impact. Denying 300, 000 claims, even at $200 each, represents $60 million in shifted costs in just two months. The speed of the system is not a tool for efficiency; it is a weapon for revenue retention.

The role of the medical director in this ecosystem is to provide a veneer of legitimacy. If a computer program sent the denial letter directly, it would be an obvious violation of medical practice laws. By inserting a human to “click and submit,” Cigna creates a legal shield. The doctor’s license sanitizes the algorithm’s output. Yet, the data betrays this arrangement. No human physician can exercise medical judgment at a rate of 50 decisions every ten seconds. The presence of the doctor is a formality; the speed of the rejection is the truth.

The Mechanics of Mass Rejection

This volume of denials is not the result of human medical professionals carefully weighing the nuances of individual patient files. It is the output of the “PxDx” (Procedure-to-Diagnosis) system, a proprietary method designed to identify discrepancies between a diagnosis code and a procedure code. When the system flags a mismatch, it does not route the claim for a second opinion or a request for more information. Instead, it queues the claim for bulk denial. Internal documents and testimony from former Cigna employees reveal that medical directors do not review these files individually. They sign off on them in batches. A former medical director admitted to ProPublica, “We literally click and submit. It takes all of ten seconds to do 50 at a time.” This “batch signature” process allows the company to maintain the legal fiction that a licensed physician reviewed the medical need of the care, while in reality, the physician acted as a rubber stamp for a computer’s decision.

The 60, 000-Claim Doctor

The operational tempo required to hit 300, 000 denials in two months produces statistical anomalies that standard medical practice. In one reported instance, a single Cigna medical director denied 60, 000 claims in a single month. To understand the impossibility of this task under traditional medical standards, one must break down the mathematics of the workday.

If a doctor were to spend even five minutes reviewing a patient’s medical history, a conservative estimate for a genuine medical need determination, they could review perhaps 12 claims an hour. To reach 60, 000 denials, that doctor would need to work 5, 000 hours in a month, which is mathematically impossible as a month contains only 720 hours. The 60, 000 figure serves as irrefutable proof that no meaningful medical review occurred. The “review” was a digital signature applied to a spreadsheet.

Targeting Low-Cost, High-Volume Procedures

The 300, 000 denials were not distributed randomly across complex surgeries or rare treatments. The PxDx system specifically low-cost, high-volume tests. Vitamin D screenings, autonomic nervous system testing, and ultrasounds appear frequently in the denial logs. This strategy maximizes financial return while minimizing consumer pushback. A patient denied coverage for a $100, 000 surgery almost certainly appeal and involve a lawyer. A patient denied coverage for a $75 Vitamin D test is likely to pay the bill out of pocket to avoid the bureaucratic nightmare of an appeal. By aggregating hundreds of thousands of these small denials, Cigna saves millions of dollars. The “blitz” is not about medical accuracy; it is a revenue retention strategy built on the assumption of patient fatigue.

The “Medical need” Facade

Cigna defends this system by claiming it accelerates payment for approved claims and that PxDx is used only for “simple” codes. Yet, the class action lawsuit *Veinbergs v. Cigna*, filed in the Eastern District of California, challenges this characterization. The plaintiffs that Cigna wrongfully delegated its obligation to evaluate claims to the PxDx system, fraudulently misleading members into believing a doctor had assessed their case. The “medical need” standard is the core of this dispute. State laws and insurance contracts mandate that a denial based on medical need must come from a professional competent to evaluate the specific clinical problem. When a computer code dictates the denial and a doctor signs it without opening the file, the definition of “medical need” shifts from a clinical determination to a rigid algorithmic rule.

The 0. 2% Appeal Rate

The success of the PxDx blitz relies heavily on the apathy or exhaustion of the insured. Data in the *Veinbergs* lawsuit and analyzed by the Kaiser Family Foundation shows that patients appeal only about 0. 2% of denied claims. Cigna disputes this, claiming a 5% appeal rate, yet even the higher figure suggests that 95% of these bulk denials go unchallenged. This low appeal rate validates the PxDx business model. If Cigna denies 300, 000 claims and only 600 to 15, 000 are appealed, the administrative cost of processing those appeals is dwarfed by the savings from the 285, 000+ unappealed denials. The system shifts the cost of medical care from the insurer to the patient, not because the care was unnecessary, because the barrier to proving need was artificially raised by automation.

Regulatory and Legal Scrutiny

The of the 300, 000-claim blitz triggered immediate backlash. The House Energy and Commerce Committee demanded answers from Cigna, seeking specific statistics on how claims were reviewed and denied by each clinician. The committee’s inquiry focused on the chance violation of federal and state laws that require individual claim review. Cigna’s response has been to characterize the ProPublica reporting as “biased” and to insist that PxDx is an industry-standard tool for sorting codes. Yet, the raw data remains the most damning evidence. A system that allows a single employee to reject 60, 000 medical procedures in a month operates outside the boundaries of human medical practice. It is a financial filter, not a healthcare service. The two-month snapshot of 300, 000 denials provides a clear window into the operational reality of modern managed care: volume over verification, and speed over safety.

The Dashboard of Denial

The operational heart of The Cigna Group’s PxDx system is not a medical library or a consultation room, a digital dashboard designed for speed. Inside this interface, the complex, detailed reality of patient health is stripped away, replaced by a clear spreadsheet of codes and checkboxes. This is the “Click and Close” method, a term coined by the medical directors themselves to describe the mechanical act of rejecting claims in bulk. The process transforms the role of a physician from a clinical investigator into a high-speed data processor, where the primary metric of success is not diagnostic accuracy, the volume of closures. Former Cigna medical directors have described an interface that presents claims not as individual patient files, as rows in a batch list. In a traditional insurance review, a doctor might open a file, examine the patient’s medical history, review lab results, and read the attending physician’s notes to determine if a procedure was medically necessary. The PxDx system bypasses this entirely. Instead, the medical director sees a queue of “mismatches”, claims where the procedure code does not align with the diagnosis code according to Cigna’s internal list. The doctor does not need to open the patient’s chart. They do not need to see the blood work. They simply see a line item that the algorithm has already flagged for rejection. The software allows for “batch signing.” A medical director can select a block of 50 claims at once. With a single interaction, they can apply their electronic signature to all 50 denials. This functionality is the technical enabler of the 1. 2-second review average. It is physically impossible to read 50 patient names, let alone their medical histories, in the ten seconds it takes to finalize a batch. The system is designed to this blindness. By presenting the claims as a homogenous list of “errors” rather than a collection of sick patients, the interface psychologically and procedurally distances the reviewer from the human consequences of the click.

The Productivity Board

To ensure that medical directors use the “Click and Close” method to its full chance, Cigna implemented a system of surveillance and metrics. Internal documents reveal the existence of a “productivity board,” a scorecard that tracked how claims each medical director handled per month. This gamification of denial created an environment where speed was the currency of employment. Dr. Debby Day, a former Cigna medical director, testified to the immense pressure exerted by these metrics. “Deny, deny, deny. That’s how you hit your numbers,” she stated in interviews following the exposure of the system. The productivity board did not measure the accuracy of the reviews. It did not track how times a director caught a false positive in the algorithm or saved a patient from an incorrect denial. It measured throughput. A doctor who paused to “examine” a file, to actually open the records and check if the patient had a unique condition justifying the test, would see their numbers drop. They would fall to the bottom of the productivity list. This created a perverse incentive structure where diligence was punished and negligence was rewarded. The “Click and Close” method was not just an option; it was a requirement for survival within the corporate hierarchy. Supervisors monitored these dashboards closely. Directors who failed to clear their queues quickly enough faced scrutiny. The message was clear: the algorithm had already done the thinking; the doctor’s job was to provide the legal signature required by state regulations. This reduces the “medical review” to a clerical task, stripping the physician of their clinical agency. The doctor becomes a biological component of the software, a human relay switch whose only function is to legitimize the machine’s decision with a medical credential.

The Muney Doctrine

The architecture of this system can be traced back to Dr. Alan Muney, Cigna’s former Chief Medical Officer. Muney, who also implemented similar systems at other insurers, operated under a philosophy that viewed manual medical review as an “administrative hassle.” In depositions and interviews, Muney has defended the PxDx system by arguing that it simply identifies claims Cigna has a “right to deny.” His logic posits that if a diagnosis code does not match the procedure code on the pre-approved list, the claim is invalid by default, and therefore requires no further clinical investigation. This perspective relies on a rigid, binary interpretation of medicine that conflicts with the messy reality of biological systems. A patient may present with symptoms that do not fit neatly into a standard diagnosis code, yet still require a specific test to rule out serious conditions. A physician might order a Vitamin D test not because of a standard deficiency code, because of a complex interaction of medications or a history of bone fractures. The Muney Doctrine ignores these nuances. It assumes that the billing code is the total sum of the patient’s reality. By designing the system to reject “mismatches” automatically, Muney engineered a process that prioritizes the insurer’s contract language over the patient’s physiological needs. The “Click and Close” method is the operationalization of this doctrine. It is the tool that allows Cigna to Muney’s philosophy across millions of patients. Without the batch-signing capability, the cost of denying these claims would exceed the savings. If a doctor had to spend five minutes reviewing each $200 claim, the administrative cost would consume the profit. The “Click and Close” method is therefore not just a user interface feature; it is the economic engine of the entire PxDx strategy. It lowers the transaction cost of rejection to near zero, making it profitable to deny even small, low-cost claims in massive volumes.

The Nurse Buffer and the Illusion of Oversight

Cigna defends its process by claiming that nurses or other staff review these claims before they reach the medical director. yet, investigations show that this “nurse review” frequently serves as another of automated facilitation rather than a safety net. Nurses, frequently working in overseas processing centers, are tasked with preparing the denial language. They do not have the authority to override the algorithm’s logic; their role is to package the claim so that the medical director can sign it as quickly as possible. Dr. Day noted that the work from these processing centers was frequently “sloppy” or error-prone, yet the pressure to “click and close” meant that medical directors rarely had time to correct these errors. The nurse’s preparation greases the wheels for the doctor’s rubber stamp. The doctor sees a claim that has already been flagged by the computer and “prepped” by a nurse. The route of least resistance is to click “sign.” To challenge the denial would require rejecting the work of the nurse, opening the file, investigating the codes, and writing a new justification, actions that would destroy the director’s productivity metrics. This structure creates a diffusion of responsibility. The algorithm blames the code mismatch. The nurse follows the algorithm. The doctor trusts the nurse and the algorithm. No single human being takes ownership of the decision to deny care. The “medical review” becomes a hallucination, a series of bureaucratic steps that mimic the form of oversight without the substance of judgment. The patient is left with a denial letter signed by a doctor who never knew their name, never saw their chart, and spent less than two seconds considering their case.

Legal Fiction of the Signature

The output of the “Click and Close” method is a document that carries significant legal weight: a denial of coverage signed by a licensed medical doctor. In the eyes of the law, this signature certifies that a medical professional has reviewed the case and determined that the treatment was not medically necessary. This certification is the shield Cigna uses against regulatory audits and patient lawsuits. It allows them to claim that every denial was “physician-reviewed.” yet, the “Click and Close” process renders this signature a legal fiction. A signature applied to a batch of 50 unread files is not a certification of review; it is a certification of presence. It proves only that the doctor was logged into the system and capable of moving a mouse. It does not prove that they exercised medical judgment. State laws in California and other jurisdictions explicitly require that medical directors conduct a “reasonable investigation” before denying a claim. The “Click and Close” method, by its very design, precludes the possibility of reasonable investigation. When a medical director signs a batch of denials in ten seconds, they are attesting to a lie. They are asserting that they have evaluated the medical need of 50 different procedures for 50 different patients in a timeframe that is insufficient to read a single sentence. This between the legal meaning of the signature and the physical reality of the review process is the core of the fraud allegation against Cigna. The system uses the credibility of the medical license to launder the automated decisions of an algorithm, converting a computer’s “false” output into a doctor’s “no.”

The Absence of Clinical Judgment

The most serious consequence of the “Click and Close” method is the complete removal of clinical judgment from the claims process. Medicine is an interpretive science. Diagnosis codes are imperfect shorthand for complex biological realities. A “mismatch” in codes is frequently a clerical error or a reflection of a unique patient presentation, not a absence of medical need. A human reviewer, given time and access to records, can discern the difference. They can see that a patient with a history of cancer needs a specific test even if the primary diagnosis code doesn’t strictly match the standard list. The PxDx system, executed via “Click and Close,” eliminates this discernment. It enforces a rigid adherence to the list. If the code isn’t there, the claim is denied. There is no room for the “art” of medicine, nor for the exceptions that define complex care. The medical director, constrained by the interface and the productivity board, is stripped of their ability to act as a physician. They are reduced to a gatekeeper who keeps the gate locked by default. This absence of judgment is not an accident; it is the product. The system is designed to strip out the variability of human decision-making, which Cigna views as a cost, and replace it with the predictability of algorithmic denial. The “Click and Close” method ensures that this replacement is absolute. It prevents the doctor from interfering with the algorithm’s efficiency. In doing so, it transforms the medical director from a safeguard for the patient into a safeguard for the company’s bottom line, ensuring that the flow of denials remains unbroken, rapid, and immensely profitable.

The evidence points to a system where the title of “Medical Director” has been repurposed. It no longer signifies a senior clinician applying their expertise to complex cases. In the context of PxDx, it signifies a high-throughput data processor, whose primary qualification is the ability to legally sign a denial letter. The patients on the other end of these letters assume a doctor reviewed their case. The data shows that assumption is false.

The gap between the diagnosis code and the procedure code becomes the sole arbiter of coverage. The patient’s actual medical file—the notes, the history, the lab results—remains closed. The algorithm does not need to see the patient to deny the care. It only needs to see that the codes do not align with its profitable expectations.

The true genius of the PxDx system lies not in its ability to detect complex fraud, in its ruthless efficiency at harvesting low-hanging fruit. While high-cost surgeries and prolonged hospital stays trigger traditional, labor-intensive reviews, Cigna’s algorithmic dragnet focuses on the high-volume, low-dollar claims that constitute the bedrock of routine medical care. By targeting inexpensive tests and minor procedures, Vitamin D screenings, dermabrasion, autonomic nervous system testing, the insurer executes a strategy of “death by a thousand cuts.” The individual patient financial load is frequently small enough to discourage an appeal, yet the aggregate savings for the corporation are massive. This section examines the specific medical codes targeted by PxDx and the calculated economics behind denying care that costs less than the administrative price of reviewing it.

The Vitamin D Dragnet

Few examples illustrate the absurdity of the PxDx logic better than the systematic denial of Vitamin D testing. In the of American healthcare, testing for Vitamin D deficiency is a standard, preventative measure, particularly for patients exhibiting symptoms of fatigue, bone pain, or those with known risk factors like osteoporosis. For Cigna’s algorithm, yet, this common blood test represents a prime target for bulk rejection.

Investigative reporting highlighted the case of Dr. Nick van Terheyden, a physician who found himself on the receiving end of Cigna’s automated denial engine. His doctor ordered a blood test which confirmed a Vitamin D deficiency, a diagnosis that carries serious long-term risks if left untreated, including bone fractures. even with the clinical evidence, Cigna’s system flagged the claim as “not medically necessary.” The algorithm identified a mismatch: the diagnosis code submitted did not align with the pre-approved list of conditions Cigna’s computer decided warranted the test.

The circular logic employed here is maddening for providers and dangerous for patients. Cigna denied the test used to confirm the deficiency because the patient absence sufficient documentation of the deficiency prior to the test. This Catch-22 is a feature, not a bug, of the PxDx design. By rigidly enforcing a narrow set of approved diagnosis codes, the system automatically rejects claims that fall outside its binary parameters, regardless of the physician’s clinical judgment. For Dr. van Terheyden, the denial was not a medical decision made by a peer reviewing his chart; it was a digital refusal triggered by a code mismatch. He appealed, eventually winning payment after months of effort, a victory Cigna knows most patients never pursue.

Dermabrasion and the “Cosmetic” Shield

Cigna defends the PxDx system by claiming it is deployed primarily for fifty specific diagnoses where claims are frequently unnecessary or cosmetic. The company explicitly cites dermabrasion and chemical peels as examples of procedures that justify this automated scrutiny. In the public relations narrative, PxDx acts as a shield against vanity treatments disguised as medical care. The reality of the denial data suggests a far blunter instrument.

Dermabrasion is indeed used for cosmetic skin resurfacing, it is also a legitimate medical treatment for removing precancerous lesions, treating severe scarring from accidents or surgery, and managing rhinophyma. A human reviewer looking at a patient file would see the difference between a patient seeking a youthful glow and a patient needing scar revision after a traumatic injury. The PxDx algorithm, yet, absence this nuance. It sees the procedure code for dermabrasion and checks the diagnosis code. If the doctor uses a general code or one not explicitly whitelisted, the claim is instantly rejected.

This “shoot, ask questions later” method forces the patient to prove the medical need after the fact. For a procedure like dermabrasion, which can cost hundreds or thousands of dollars, the denial shifts the financial risk entirely onto the enrollee. If the patient cannot navigate the labyrinthine appeals process or if their doctor does not have the time to resubmit with different codes, Cigna keeps the money. The classification of these procedures as “commonly not medically necessary” gives the insurer cover to deny them all by default, placing the load of proof on the sick rather than the insurer.

The Autonomic Nervous System Calculation

Internal documents obtained during investigations reveal that Cigna’s executives understood exactly how much money they could extract by adding specific tests to the PxDx blacklist. One particularly damning analysis focused on Autonomic Nervous System (ANS) testing. This diagnostic tool is used to detect nerve damage caused by conditions like diabetes and autoimmune diseases, complications that, if caught early, can be managed to prevent severe disability.

Cigna’s internal assessment was cold and mathematical. The company calculated that ANS testing costs a few hundred dollars per instance. By adding this test to the PxDx auto-denial list, the insurer estimated it would reject approximately 17, 800 claims annually. The projected savings? Roughly $2. 4 million per year. The documents show that executives acknowledged this move would likely result in “negative customer experience” and increased out-of-pocket costs for patients. They proceeded anyway.

This specific case strips away the pretense of “medical need.” The decision to target ANS testing was not based on a sudden discovery that the test was ineffective or that doctors were prescribing it fraudulently. It was a financial calculation. The cost of the test was low enough that individual denials might fly under the radar, the volume was high enough to generate millions in profit. The “negative customer experience”, a euphemism for patients being denied coverage for nerve damage screenings, was deemed an acceptable price for the $2. 4 million added to the bottom line.

Preventative Screenings: The High of Low Cost

The danger of the PxDx system extends beyond financial annoyance into the of life-threatening negligence. Class action lawsuits filed against Cigna allege that the algorithm has been used to deny preventative screenings for high-risk patients. One plaintiff, diagnosed with Lynch syndrome, a genetic condition that significantly increases the risk of colon and other cancers, was denied coverage for a colonoscopy and endoscopy. These are not optional procedures for a Lynch syndrome patient; they are serious, life-saving surveillance measures required to catch aggressive cancers early.

Another plaintiff in the California class action was denied coverage for an ultrasound, even with being identified as at risk for ovarian cancer. In these instances, the PxDx system’s rigid code matching failed to account for the patient’s specific medical history. The algorithm saw a “routine” test code and a diagnosis that didn’t fit its narrow acceptance criteria, and issued a denial. The speed of the review, 1. 2 seconds, precludes any possibility that a medical director considered the patient’s genetic predisposition or the fatal consequences of a missed diagnosis.

Denying these screenings saves Cigna money in the current fiscal quarter. A colonoscopy costs a few thousand dollars; an ultrasound costs a few hundred. yet, the long-term cost of treating late-stage cancer is astronomical. By denying the low-cost screening, Cigna is gambling that the patient either pay out of pocket or that the cancer won’t develop until the patient is insured by someone else. It is a cynical game of hot potato played with human lives.

The Economics of Apathy

The targeting of low-cost care is underpinned by a concept known as the “economics of apathy.” Cigna knows that the likelihood of a patient appealing a denial drops significantly as the dollar amount decreases. If a patient is denied a $100, 000 heart surgery, they fight to the ends of the earth. If they are denied a $50 Vitamin D test or a $200 screening, they are statistically likely to give up.

Industry data and Cigna’s own internal metrics suggest that only about 0. 2% to 5% of denials are ever appealed. For low-dollar claims, the “hassle factor” is the insurer’s greatest ally. The time and energy required to print forms, call customer service, gather medical records, and mail appeals frequently outweigh the cost of the bill itself. Patients simply pay the $50 and move on.

For Cigna, this is the perfect crime. If the PxDx system denies 100, 000 claims worth $50 each, the total value is $5 million. If only 5% of patients appeal and win, Cigna pays out $250, 000. The remaining $4. 75 million is pure profit, generated simply by saying “no” and waiting for the patient to blink. The administrative cost of manually reviewing those 100, 000 claims would likely exceed the value of the claims themselves. By automating the denial, Cigna eliminates the administrative cost and the claims cost simultaneously.

The “Click and Close” Reality

The method that enables this strategy is the “click and close” review process described by former Cigna medical directors. Because the algorithm handles the heavy lifting of identifying the “mismatches,” the human doctors are reduced to rubber stamps. They do not need to evaluate whether a specific patient really needs a Vitamin D test; they only need to verify that the computer flagged it. This allows them to process denials in bulk, clearing batches of hundreds in minutes.

This industrial- rejection of low-cost care fundamentally alters the insurance contract. Patients pay premiums with the expectation that medically necessary care be covered. Cigna’s PxDx system inverts this, creating a system where care is denied by default unless the diagnosis code perfectly matches a secret list. The load of medical need is no longer on the doctor to prescribe, on the patient to litigate. In the context of low-cost screenings and tests, this load is frequently too heavy to bear, leaving millions of dollars in legitimate claims unpaid and thousands of patients without the diagnostic answers they paid to receive.

The “Reasonable Investigation” Test

The legal concept of “reasonableness” is central to insurance law. A “reasonable investigation” implies that the insurer must gather and review all available information before making a decision that affects a patient’s financial liability. In the class-action lawsuits *Vanara v. Cigna* and *Kisting-Leung v. Cigna*, plaintiffs allege that Cigna systematically violates this duty. The complaints detail how the PxDx system bypasses the necessary steps of file review, delegating the “medical need” determination to a set of rigid rules that cannot account for biological nuance. In March 2025, U. S. District Judge Dale Drozd provided a significant judicial rebuke to Cigna’s defense of this practice. Ruling on a motion to dismiss, Judge Drozd rejected the insurer’s argument that a medical director “pushing the button” satisfied the plan’s requirement for a medical need review. The court found that interpreting the plan to allow an algorithm to make the decision, provided a human performs the final keystroke, conflicts with the plain language of the contract and constitutes an abuse of discretion. This ruling stripped away the veneer of compliance Cigna had constructed, exposing the batch-review process as a chance breach of fiduciary duty under ERISA.

Breaching the Covenant of Good Faith

Beyond specific statutes, every insurance contract carries an implied covenant of good faith and fair dealing. This legal principle obligates the insurer to give at least as much consideration to the patient’s interests as it does to its own. By deploying a system designed to reject claims in bulk without individual assessment, Cigna is accused of prioritizing administrative speed and cost containment over its contractual obligation to pay valid claims. The *Vanara* complaint that Cigna “wrongfully delegated” its obligation to evaluate claims to the PxDx system. The software functions as a barrier to coverage, shifting the load of proof entirely onto the patient. When a claim is denied via PxDx, the patient receives a form letter stating the service was not medically necessary. To overturn this, the patient must navigate a complex appeals process. Data suggests that fewer than 0. 2% of policyholders appeal these denials, meaning Cigna retains the money for 99. 8% of the rejected claims, regardless of their actual medical validity. This statistic supports the legal argument that the system is not a method of claims processing, a method of revenue retention that relies on patient fatigue.

Regulatory Evasion and Scrutiny

Cigna has defended PxDx by categorizing it as a tool for “post-service” claims processing rather than a denial of care. They that because the service has already been rendered, they are not preventing treatment, only payment. Regulators view this distinction as semantic. Whether the denial happens before or after the procedure, the financial impact on the patient is identical. If the insurance company refuses to pay, the patient is left with the bill. The Connecticut Insurance Department and the California Department of Insurance have both initiated inquiries into these practices. In Connecticut, regulators specifically questioned whether the use of such algorithms violates the state’s requirement for a “reasonable investigation based on all available information.” While Cigna stated that PxDx is not used for Connecticut-insured business, the widespread nature of the software across its national network has drawn federal attention. The House Energy and Commerce Committee’s investigation highlights the concern that these automated denials are not errors a calculated business strategy that undermines the foundational pledge of health insurance.

The Human Element as a Legal Fiction

The presence of a medical director’s signature on a denial letter is intended to serve as proof of medical review. In the context of PxDx, legal challengers assert this signature is a legal fiction. If a doctor signs 60, 000 denials in a single month, as records indicate one Cigna director did, they are not acting as a physician. They are acting as a data processor. State laws requiring a “licensed physician” to make medical need determinations presuppose that the physician is using their medical training to evaluate the patient’s condition. When that physician is removed from the loop—relegated to clicking “approve” on a batch of computer-generated rejections—the insurer violates the spirit and the letter of the law. The “thorough and objective” standard is not a suggestion; it is a safeguard against the exact type of automated indifference PxDx represents. By removing the human element of investigation while retaining the human element of authorization, Cigna attempts to satisfy regulatory requirements without performing the actual work those regulations demand. This gap between the appearance of compliance and the reality of automation is the focal point of the ongoing legal battles that threaten to the PxDx framework.

The Productivity Scorecard

Cigna managers use a specific dashboard to monitor the output of their medical directors. This system does not track the accuracy of a diagnosis or the patient health outcome. It tracks “transaction volume” and “handle time.” These two metrics dominate the performance reviews of the doctors employed by the insurer. A medical director who spends time reading a patient file risks falling behind. The dashboard displays their numbers against those of their peers. This comparative data creates a competitive pressure to process claims faster. Former medical director Dr. Linda Day provided testimony regarding this pressure. She stated that the dashboard sent a clear message to the staff. Speed was the primary value. In her experience, managers did not ask if she made the correct medical decision. They asked how long it took her to decide. The system allocated specific time slots for different tasks. A prior authorization might get four minutes. A hospital discharge decision might get slightly more. for PxDx claims, the time allocation was zero. The system was designed for bulk processing.

1. 2 Seconds Per Decision

The most revealing statistic from the ProPublica investigation involves the average time spent on a PxDx denial. Analysis of Cigna records showed that medical directors denied over 300, 000 claims in a two-month period in 2022. The average time stamp for these denials was 1. 2 seconds. This duration is physically insufficient to read a patient name, let alone a medical record. It is the time required to move a mouse cursor and click a button. This speed is only possible because the system allows for “batch signing.” A medical director does not open individual files. They see a list of claims that the PxDx algorithm has already flagged for rejection. The doctor then selects the entire batch and applies a digital signature to all of them at once. This action formally denies coverage for hundreds or thousands of patients in a single motion. The 1. 2-second average is a mathematical result of this bulk processing. It proves that no human review occurred.

The 60, 000 Claim Month

The of this operation becomes clear when examining the output of individual doctors. Internal records show that Dr. Cheryl Dopke, a medical director for Cigna, denied roughly 60, 000 claims in a single month. To achieve this number through genuine review, a doctor would need to work without sleep or breaks for thirty days straight. Even then, they would have to complete a review every 43 seconds. The reality is that Dr. Dopke likely spent a fraction of that time. She used the batch function to clear queues of flagged claims. This volume of denials generates significant value for Cigna. Each denial represents a payment the company does not make. By automating the rejection and having a doctor sign off in bulk, Cigna avoids the administrative cost of a nurse review. Dr. Alan Muney, the architect of the PxDx system, admitted this purpose. He stated that requiring a manual review for each claim would be an “administrative hassle.” The system removes that hassle. It replaces clinical investigation with a rubber stamp.

“Click and Close”

The culture inside the medical review department reflected these priorities. Former employees described a “click and close” method. Doctors would open the dashboard, select the pending denials, and submit them. Dr. Day recalled the mantra she felt compelled to follow: “Deny, deny, deny. That’s how you hit your numbers.” The dashboard rewarded this behavior. A doctor who paused to investigate a gap would see their handle time increase. Their transaction volume would drop. Their ranking on the scorecard would suffer. This gamification of medical denials turns the role of the medical director upside down. In a functional healthcare system, the medical director acts as a safeguard. They ensure that administrative rules do not block necessary care. At Cigna, the dashboard turns them into an enforcement arm of the algorithm. The doctor becomes a method to legitimize the computer’s decision. They provide the legal signature required by state regulations without performing the labor those regulations intend.

Financial Incentives

The pressure to maintain high denial speeds was not just social. It was financial. Performance evaluations the dashboard metrics. These evaluations influenced bonuses and stock awards. Cigna denies that compensation is tied directly to denial volume. Yet the link between “productivity” and reward is clear in the corporate structure. A “productive” doctor is one who clears the queue. The only way to clear the PxDx queue is to accept the algorithm’s recommendations in bulk. If a medical director rejected the algorithm’s suggestion and paid a claim, it would require manual intervention. That takes time. It lowers the “efficiency” score. Therefore, the financial incentives align perfectly with the denial of care. The doctor protects their own standing and income by processing rejections as quickly as possible. The patient, unaware of this internal scorecard, assumes their claim received a fair evaluation.

Regulatory Evasion

State laws require a “thorough, fair, and objective” investigation of claims. The existence of the productivity dashboard suggests a violation of this standard. A review measured in seconds cannot be thorough. A process that penalizes doctors for taking time cannot be fair. The dashboard proves that Cigna designed a workflow where objective investigation is an obstacle to performance. The company built a system that actively discourages the very duty it is legally obligated to perform. The dashboard data also contradicts Cigna’s public defense. The company claims that PxDx is used for simple, low-cost tests where the diagnosis code does not match the procedure. They this is a standard administrative check. the volume of 300, 000 denials in two months shows it is a mass-market strategy. The 1. 2-second review time proves that no human intelligence is applied to these “administrative” checks. The computer decides. The doctor signs. The dashboard records the speed. The patient pays the bill.

The Kisting-Leung Allegations

Suzanne Kisting-Leung’s experience served as the primary exhibit for the plaintiffs’ argument that Cigna had abandoned its duty to conduct “thorough, fair, and objective” investigations. According to court documents, Kisting-Leung’s physician referred her for a transvaginal ultrasound due to a suspected risk of ovarian cancer. The imaging revealed a dermoid cyst on her left ovary, a medical finding that validates the need of the procedure. Yet, Cigna’s system issued a denial. The insurer refused to cover the ultrasound, classifying it as not medically necessary. Kisting-Leung received a bill for approximately $198, followed by a second denial for a subsequent ultrasound that left her with a total debt of over $700. The complaint argued that no medical director could have genuinely reviewed her file and concluded the screening was unnecessary given the cancer risk. Instead, the lawsuit alleged her claim was swept up in a PxDx batch, rejected instantly because the diagnostic code submitted did not perfectly align with the narrow list of approved codes for that procedure. The core legal argument in *Kisting-Leung* rested on the assertion that Cigna violated California’s Unfair Competition Law (UCL). By delegating the review process to an algorithm that spent an average of 1. 2 seconds per claim, a figure from the ProPublica investigation, the plaintiffs contended that Cigna engaged in a fraudulent business practice. The “click and close” method, they argued, rendered the pledge of medical review a sham, designed solely to optimize corporate profits at the expense of patient health.

The Veinbergs Complaint

Following the initial filing, a related class action was brought by Hannah Veinbergs in the Southern District of California. Veinbergs’ case expanded the scope of the allegations, focusing on denials related to mental health services. Her complaint detailed a visit to a primary care physician for a mental health concern, which Cigna subsequently denied. Like Kisting-Leung, Veinbergs alleged that her claim was never subjected to a meaningful review by a clinician. The *Veinbergs* lawsuit emphasized the “batching” method, accusing Cigna of allowing medical directors to sign off on hundreds of denials simultaneously without opening a single patient file. The complaint described this as an “illegal scheme” to bypass state mandates that require insurers to evaluate the specific clinical circumstances of each patient. By automating the rejection, Cigna allegedly shifted the administrative load to the patient, banking on the statistical likelihood that few would navigate the complex appeals process.

Cigna’s “Standing” Defense

Cigna mounted a vigorous defense, attacking the factual basis of the plaintiffs’ claims rather than the mechanics of the PxDx system itself. The insurer argued that the specific claims in the lawsuits, including those of Kisting-Leung and Veinbergs, were not actually processed by the PxDx algorithm. Cigna submitted affidavits from medical officers, such as Dr. Julie B. Kessel, asserting that these denials resulted from standard manual reviews or other administrative processes. This strategy proved in the early stages of litigation. In late 2023, the *Veinbergs* case faced a voluntary dismissal, a development that legal analysts attributed to Cigna’s evidence that the plaintiff absence “standing”, meaning she had not personally suffered the specific injury (an algorithmic denial) alleged in the complaint. This tactical maneuver allowed Cigna to avoid a direct trial on the legitimacy of PxDx in that specific instance, shifting the battlefield back to the *Kisting-Leung* docket.

The March 2025 Ruling

The litigation reached a pivotal moment on March 31, 2025, when U. S. District Judge Dale Drozd issued a ruling in *Kisting-Leung v. Cigna Corp*. The judge granted Cigna a partial victory by dismissing claims from certain plaintiffs who could not prove their denials originated from the PxDx system. This whittled down the class to those who could definitively link their rejections to the automated software. Yet, Judge Drozd allowed the core of the lawsuit to proceed. He rejected Cigna’s argument that the Employee Retirement Income Security Act (ERISA) preempted the state law claims. The court found that the “savings clause” in ERISA, which permits states to regulate insurance practices, applied to California’s requirement for “thorough and objective” claim investigations. This ruling was significant; it established that federal law does not automatically shield insurers from state-level consumer protection suits regarding algorithmic processing. The judge permitted the plaintiffs to amend their complaint, keeping the challenge to the PxDx system alive and setting the stage for a chance trial on the merits of automated medical need reviews.

Broader Legal

The survival of the *Kisting-Leung* case, even in a narrowed form, signaled a serious risk for the insurance industry. It validated the legal theory that using software to bypass human review could constitute a breach of fiduciary duty and a violation of state insurance codes. Parallel litigation, such as the *Van Pelt* case filed in Connecticut, echoed these arguments, suggesting a coordinated legal effort to force transparency in how insurers use automation. The courtroom battles revealed a distinct pattern: insurers defend algorithmic denials by claiming they are “industry standard” and “,” while plaintiffs characterize them as “fraudulent” and “abandonment of care.” The *Kisting-Leung* proceedings also highlighted the difficulty of proving exactly *how* a claim was denied, as the internal routing of a claim through systems like PxDx is frequently invisible to the patient until discovery forces the insurer to reveal the audit logs.

As the litigation moved forward in 2026, the focus shifted to discovery—the phase where Cigna would be forced to hand over the raw data showing exactly which claims were auto-denied and how much time medical directors truly spent on them. The “1. 2 seconds” statistic, once just a journalistic finding, was poised to become a piece of forensic evidence in a federal courtroom.